ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 135 filers reported holding ASCENDIS PHARMA A/S in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,111,000 | -44.8% | 18,334 | -43.5% | 1.49% | -44.7% |
| Q1 2019 | $3,823,000 | +55.6% | 32,477 | -17.2% | 2.69% | +38.8% |
| Q4 2018 | $2,457,000 | -9.9% | 39,217 | +1.9% | 1.94% | +8.5% |
| Q3 2018 | $2,727,000 | +1.1% | 38,486 | -5.0% | 1.78% | -0.2% |
| Q2 2018 | $2,696,000 | -12.2% | 40,528 | -13.6% | 1.79% | -18.4% |
| Q1 2018 | $3,069,000 | +50.7% | 46,933 | -7.6% | 2.19% | +25.5% |
| Q4 2017 | $2,036,000 | -6.2% | 50,813 | -15.1% | 1.75% | +1.7% |
| Q3 2017 | $2,171,000 | +31.6% | 59,876 | +0.7% | 1.72% | +17.8% |
| Q2 2017 | $1,650,000 | -29.4% | 59,455 | -28.7% | 1.46% | -33.9% |
| Q1 2017 | $2,336,000 | +10.1% | 83,411 | -20.4% | 2.20% | +5.6% |
| Q4 2016 | $2,121,000 | – | 104,793 | – | 2.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |